Salvage radiotherapy after high-intensity focused ultrasound treatment for localized prostate cancer: feasibility, tolerance and efficacy
DOI:
https://doi.org/10.5489/cuaj.18Abstract
Background: The objective of this study is to evaluate the feasibility,tolerance and efficacy of salvage external beam radiotherapy(EBRT) in persistent or recurrent prostate cancer after failed highintensity focused ultrasound (HIFU) therapy.
Methods: We reviewed data on tolerance and oncologic outcomesfor all patients with biopsy-proven locally recurrent or persistentprostate cancer who underwent salvage EBRT in our departmentbetween April 2004 and June 2008. Minimum follow-up for inclusionwas 2 years. Failure with EBRT was defined as biochemicalrelapse (Phoenix definition) or introduction of androgen deprivationtherapy (ADT). Gastrointestinal and urinary toxicity and urinary stressincontinence were scored at 12 and 24 months (Radiation TherapyOncology Group and Ingelman Sundberg rating, respectively).
Results: The mean age of the patients was 68.8 years (range: 60-79).Mean prostate-specific antigen (PSA) before EBRT was 5.57 ng/mL(range: 2.5-14.8). Median follow-up was 36.5 ± 10.9 months(range: 24-54). No patient received adjunctive ADT. The EBRTcourse was well-tolerated and completed by all patients. The meanPSA nadir was 0.62 ng/mL (range: 0.03-2.4) and occurred after amedian of 22 months (range: 12-36). One patient experiencedbiochemical failure and was prescribed ADT 30 months after EBRT.The disease-free survival rate was 83.3% at 36.5 months. Therewas no major EBRT-related toxicity at 12 or 24 months.
Conclusions: Our early clinical results confirm the feasibilityand good tolerance of salvage radiotherapy after HIFU failure.Oncological outcomes were promising. A prospective study withlonger follow-up is needed to identify factors predictive of successfor salvage EBRT therapy after HIFU failure.
Downloads
References
Yancik R. Population aging and cancer: a cross-national concern. Cancer J 2005;11:437-41.
Aus G, Abbou CC, Bolla M, et al. European association of Urology. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51.
Gelet A, Chapelon JY, Bouvier R, et al. Local control of prostate cancer by transrectal High intensity focused
ultrasound therapy: preliminary results. J Urol 1999;161:156-62.
Blana A, Walter B, Rogenhofer S, et al. High intensity focused ultrasound for the treatment of localized
prostate cancer: 5-year experience. Urology 2004;63:297-300.
Blana A, Murat FJ, Walter B, et al. First analysis of the long-term result with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008;53:1194-201.
Gelet A, Chapelon JY, Bouvier R, et al. Transrectal High intensity focused ultrasound for treatment of localized prostate cancer: factors influencing the outcomes. Eur Urol 2001;40:124-9.
Challacombe BJ, Murphy DG, Zakri R, et al. High intensity focused ultrasound for localized prostate cancer: initial experience with a 2-years follow-up. BJU Int 2009;104:200-4.
Blana A, Rogenhofer S, Ganzer R, et al. Eight years’ experience with High intenstiy focused ultrasonography for treatment of localized prostate cancer. Urology 2008;72:1329-34.
Mearini l, D’Urso l, Collura D, et al. Visually directed transrectal High intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 2009 ;181:105-11; discussion 111-2.
Uchida T, Ohkusa H, Yamashita H, et al. Five years experience of transrectal high-intensity focused ultrasound
using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006;13:228-33.
Misraï V, Roupret M, Chartier-Kastler, et al. Oncologic control provided by HIFU therapy as single treatment
in men with clinically localized prostate cancer. World J Urol 2008;26:481-5.
Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
Lukka H, Waldron T, Chin J, et al. High-intensity focused ultrasound for prostate cancer: a practice guideline.
Can Urol Assoc J 2010;4:232-6.
Soulié M, Beuzeboc P, Cornud F, et al. Recommandations 2007 en onco-urologie. Prog Urol 2007;17:1157-88.
Poissonnier L, Chapelon JY, Rouvière O, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381-7.
Blana A, Murat FJ, Walter B, et al. First analysis of the long-term result with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008;53:1194-201.
Stolzenburg JU, Bynens B, Do M, et al. Salvage laparoscopic extraperitoneal radical prostatectomy after failed High-intensity focused ultrasound and radiotherapy for localized prostate cancer. Urology 2007;70:956-60.
Liatsikos E, Bynens B, Rabenalt R, et al. Treatment of patients after failed High intensity focused ultrasound
and radiotherapy for localized prostate cancer: salvage laparoscopic extraperitoneal radical prostatectomy.
J Endourol 2008;22:2295-8.
Rebillard X, Soulié M, Chartier-Kastler E, et al. High-intensity focused ultrasound in prostate cancer: a
systematic literature review of the French Association of Urology. BJU Int 2008;101:1205-13.
Pasticier G, Chapet O, Badet L, et al. Salvage radiotherapy after high-intensity focused ultrasound for
localized prostate cancer: early clinical results. Urology 2008;72:1305-9.
Blana A, Brown SC, Chaussy C, et al. High-intensity focused ultrasound for prostate cancer : comparative
définitions of biochemical failure. BJU Int 2009;104:1058-62.
Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or
without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOGASTRO
Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
Ingelman-Sundberg A. Urinary incontinence in women. North Med 1953;50:1751-2.
Brooks JP, Albert PS, Wilder RB, et al. Long-term salvage radiotherapy outcome after radical prostatectomy
and relapse predictors. J Urol 2005;174:2204-8.
Catton C. Post-operative radiotherapy following radical prostatectomy. EAU Update Series 2005;3:107-16.
Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract
Urol 2005;2:174-82.
Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after
radical prostatectomy. JAMA 2004;291:1325-32.
Murat FJ, Poissonnier L, Rabilloud M, et al. Mid-term results demonstrate salvage High-Intensity Focused
Ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option. Eur Urol 2008;55:640-9.
Chalasani V, Martinez CH, Williams A, et al. Histological changes in the human prostate after radiotherapy
and salvage high intensity focused ultrasound. Can Urol Assoc J 2010;4:e100-2.
Blana A, Rogenhofer S, Ganzer R, et al. Morbidity associated with repeated transrectal high-intensity
focused ultrasound treatment of localized prostate cancer. World J Urol 2006;24:585-90.
Ganzer R, Rogenhofer S, Walter B, et al. PSA nadir is a significant predictor of treatment failure after
High-intensity focused ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 2008;53:547-53.
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.